EULAR 2021 Virtual Congress - Scleroderma, myositis and related syndromes

June 5, 2021 • 10:30 am CEST

Poster: Long-term Safety and Efficacy of Lenabasum during 3 Years in an Open-Label Extension (OLE) of a Phase 2 Study of Lenabasum in Refractory Skin Disease in Dermatomyositis (DM)

EULAR 2021 Virtual Congress - Progress in myositis and scleroderma research - I

June 3, 2021 • 10:25am CEST

Presentation: Phase 3 Trial of Lenabasum, a CB2 Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc)

New York Academy of Sciences Webinar

January 27, 2021

Presentation